SCHEDULE: OrbiMed Reports Stake Reduction in Adicet Bio
Schedule 13D Amendment
OrbiMed Advisors and affiliated entities have reduced their beneficial ownership in Adicet Bio, Inc. by over 1%, reporting a combined stake of 8.8% as of April 10, 2026.
Summary
- OrbiMed Advisors LLC and its affiliated entities (collectively, the "Reporting Persons") have filed an amendment to their Schedule 13D, reporting a decrease in their beneficial ownership of Adicet Bio, Inc. common stock.
- This reduction in ownership is due to transactions that occurred on April 7, 8, and 9, 2025.
- As of April 10, 2026, the Reporting Persons collectively beneficially own 844,787 shares of Adicet Bio, Inc. common stock, representing approximately 8.8% of the outstanding shares.
- This filing (Amendment No. 9) is being made because the beneficial ownership decreased by more than 1% as a result of these transactions.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this filing as slightly negative due to the reported stake reduction by a significant investor, indicating a potential decrease in confidence or a strategic portfolio adjustment.
Negatives
- OrbiMed Advisors and its affiliates have sold a significant portion of their holdings in Adicet Bio, Inc., reducing their stake by over 1%.
Future Outlook
The Reporting Persons intend to review their investment in Adicet Bio, Inc. based on various factors and may take actions they deem appropriate, including acquiring or disposing of securities.
Industry Context
StockSavvy.ai notes that significant stake reductions by major investors like OrbiMed can signal a shift in sentiment or strategy, prompting close observation by the market regarding the company's future prospects.
Stakeholder Impact
- Shareholders may view the reduction in OrbiMed's stake as a potential negative signal, possibly influencing share price.
Next Steps
- Reporting Persons will continue to review their investment in Adicet Bio, Inc.
- Reporting Persons may acquire or dispose of additional securities of Adicet Bio, Inc. based on their review and market conditions.
Key Dates
| Date | Description |
|---|---|
| 2018-01-30 | Original Schedule 13D filing date. |
| 2019-03-25 | Amendment No. 1 filing date. |
| 2020-09-18 | Amendment No. 2 filing date. |
| 2021-02-19 | Amendment No. 3 filing date. |
| 2021-12-14 | Amendment No. 4 filing date. |
| 2023-06-29 | Amendment No. 5 filing date. |
| 2024-01-29 | Amendment No. 6 filing date. |
| 2024-03-21 | Amendment No. 7 filing date. |
| 2025-10-10 | Amendment No. 8 filing date. |
| 2025-04-07 | Date of sale of 29,319 shares by OIP at $6.53 per share. |
| 2025-04-07 | Date of sale of 2,400 shares by OIP at $6.38 per share. |
| 2025-04-08 | Date of sale of 32,523 shares by OIP at $6.29 per share. |
| 2025-04-08 | Date of sale of 40,417 shares by OIP II at $6.52 per share. |
| 2025-04-09 | Date of sale of 78,499 shares by Genesis at $6.80 per share. |
| 2026-04-07 | Event requiring filing of this statement (decrease in beneficial ownership). |
| 2026-04-08 | Date of filing of Amendment No. 9. |
| 2026-04-10 | Date of signatures on the Schedule 13D and Joint Filing Agreement. |
| 2026-03-12 | Date of Adicet Bio, Inc.'s Annual Report on Form 10-K, which stated 9,596,407 shares outstanding. |
Recommendation
holdThe filing indicates a reduction in holdings by a significant investor, which could be interpreted negatively. However, without further information on the reasons for the sale or the company's performance, a 'hold' recommendation is prudent, suggesting investors monitor future developments.
Keywords
Schedule 13D, Adicet Bio, OrbiMed Advisors, beneficial ownership, stake reduction, SEC filing, investment management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.